Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type2 diabetes mellitus: Adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model

Geriatrics and Gerontology International

Volumn 12, Issue SUPPL.1, 2012, Pages 88-102

  Shinozaki, Tomohiro ^a   Matsuyama, Yutaka ^a   Iimuro, Satoshi ^a   Umegaki, Hiroyuki ^c   Sakurai, Takashi ^d,e   Araki, Atsushi ^b   Ohashi, Yasuo ^a   Ito, Hideki ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b Tokyo Metropolitan Institute of Gerontology   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^e KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atorvastatin; Cardiovascular event; Diabetes related event; Time dependent confounding; Type2 diabetes mellitus

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; AGED; ANGINA PECTORIS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; FOLLOW UP; GANGRENE; GERIATRIC PATIENT; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; JAPANESE; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETINOPATHY; RISK ASSESSMENT; STATISTICAL ANALYSIS; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; PROPORTIONAL HAZARDS MODELS; PYRROLES;

EID: 84858761210     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2011.00816.x     Document Type: Article

References (40)

1. Grundy SM, Cleeman JI, Merz CN etal. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227-239.
2. De Backer G, Ambrosioni E, Borch-Johnsen K etal. for the Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Eur Heart J 2003; 24: 1601-1610.
3. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R etal. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125.
4. Brugts JJ, Yetgin T, Hoeks SE etal. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376. doi: 10.1136/bmj.b2376.
5. Mills EJ, Wu P, Chong G etal. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170, 255 patients from 76 randomized trials. Q J Med 2011; 104: 109-124.
6. Teramoto T, Sasaki J, Ueshima H etal. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007; 14: 45-50.
7. Colhoun HM, Betteridge DJ, Durrington PN etal. Primary prevention of cardiovascular disease with atorvastatin in type2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
8. Collins R, Armitage J, Parish S, Sleigh P, Peto R, for the Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
9. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type2 diabetes. N Engl J Med 2003; 348: 383-393.
10. Keech A, Colquhoun D, Best J etal. for the LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003; 26: 2713-2721.
11. Kojima S, Sakamoto T, Ogawa H etal. for the Multicenter Study for Aggressive Lipid-lowering Strategy by HMG-CoA Reductase Inhibitors Investigators. Standard-dose statin therapy provides incremental clinical benefits in normocholesterolemic diabetic patients. Circ J 2010; 74: 779-785.
12. Wenger NK, Lewis SJ, Herrington DM, Bittner V, FK W. Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007; 147: 1-9.
13. Ito H, Ouchi Y, Ohashi Y etal. A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE). J Atheroscler Thromb 2001; 8: 33-44. [Erratum in J Atheroscler Thromb 2001; 8: following 100].
14. Neil HA, DeMicco DA, Luo D etal. for the CARDS Study Investigators. Analysis of efficacy and safety in patients aged 65-75 years at randomization: collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 2006; 29: 2378-2384.
15. Robins JM, Blevins D, Ritter G, Wulfsohn M. G-estimation of the effect of prophylaxis therapy for pneumocystis carinii pneumonia on the survival of AIDS patients. Epidemiology 1992; 3: 319-336.
16. Robins JM, Hernán MA. Estimation of the causal effects of time-varying exposures. In: Fitzmaurice G, Davidian M, Verbeke G, Molenberghs G, eds. Longitudinal Data Analysis. New York: Chapman and Hall/CRC Press, 2008; 553-599.
17. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550-560.
18. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11: 561-570.
19. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Stat Assoc 2001; 96: 440-448.
20. Mark SD, Robins JM. Estimating the causal effect of smoking cessation in the presence of confounding factors using a rank preserving structural failure time model. Stat Med 1993; 12: 1605-1628.
21. Witteman J, D'Agostino RB, Stijnen T etal. G-estimation of causal effects: isolated systolic hypertension and cardiovascular death in the Framingham Study. Am J Epidemiol 1998; 148: 390-401.
22. Robins JM. Structural nested failure time models. In: Armitage P, Colton T, eds. The Encyclopedia of Biostatistics. Chichester: JohnWiley and Sons, 1998; 4372-4389.
23. Hernán MA, Cole SR, Margolick J, Cohen M, Robins JM. Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiol Drug Saf 2005; 14: 477-491.
24. Araki A, Iimuro S, Sakurai T etal. Long-term multiple risk factor interventions in Japanese elderly people with diabetes mellitus: the Japanese Elderly Diabetes Intervention Trial (J-EDIT): study design, baseline characteristics, and effects of intervention. Geriatr Gerontol Int 2012; 12 (Suppl. 1): 7-17.
25. Umegaki H, Iimuro S, Kaneko T etal. Factors associated with lower Mini Mental State Examination scores in elderly Japanese diabetes mellitus patients. Neurobiol Aging 2008; 29: 1022-1026.
26. Sakurai T, Iimuro S, Araki A etal. Age-associated increase in abdominal obesity and insulin resistance, and usefulness of AHA/NHLBI definition of metabolic syndrome for predicting cardiovascular disease in Japanese elderly with type2 diabetes mellitus. Gerontology 2010; 56: 141-149.
27. Diggle PJ, Heagerty P, Liang K-Y, Zeger SL. Analysis of Longitudinal Data, 2nd edn. Oxford: Oxford Univ. Press, 2002.
28. Hernán MA, Brumback B, Robins JM. Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med 2002; 21: 1689-1709.
29. D'Agostino RB, Lee M-L, Belanger AJ. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med 1990; 9: 1501-1515.
30. Preiss D, Seshasai SR, Welsh P etal. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305: 2556-2564.
31. Waters DD, Ho JE, DeMicco DA etal. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011; 57: 1535-1545.
32. Sattar N, Preiss D, Murray HM etal. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742.
33. VanderWeele TJ. Marginal structural models for the estimation of direct and indirect effects. Epidemiology 2009; 20: 18-26.
34. Oba K, Sato T, Ogihara T, Saruta T, Nakao K. How to use marginal structural models in randomized trials to estimate the natural direct and indirect effects of therapies mediated by causal intermediates. Clin Trials 2011; 8: 277-287.
35. Goetgeluk S, Vansteelandt S, Goetghebeur E. Estimation of controlled direct effects. J Roy Stat Soc Ser B 2008; 70: 1049-1066.
36. Shinozaki T, Matsuyama Y, Ohashi Y. Estimating controlled direct effects for time-varying treatments using structural nested mean models. 2011. Joint Statistical Meetings, Miami Beach, FL, July 30-August 4, 2011. Abstract 301065.
37. Suarez D, Borrás R, Basagaña X. Differences between marginal structural models and conventional models in their exposure effect estimates: a systematic review. Epidemiology 2011; 22: 586-588.
38. Motzer RJ, Escudier B, Oudard S etal. for the RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-4265.
39. VanderWeele TJ. Concerning the consistency assumption in causal inference. Epidemiology 2009; 20: 880-883.
40. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008; 168: 656-664.